Evaluation of Anti-asthmatic Activities of Ixora coccinea Linn (Rubiaceae)
Ixora coccinea L. (Rubiaceae) possess anti-inflammatory and antitussive properties. It is traditionally used for various respiratory ailments including catarrhal bronchitis cough and asthma. In the present study we investigated anti-asthmatic properties of an hydroalcoholic leaf extract of I. coccinea in an ovalbumin (OVA)-induced asthmatic rat model. We also evaluated the anti-allergic property of the extract by Abdominal Wall (AW) method and histamine-induced cutaneous reaction. Rats were sensitized with intraperitoneal (i.p.) ovalbumin and challenged by OVA intranasally to induce chronic airway inflammation. Randomized treatment groups of sensitized rats received I. coccinea extract or distilled water. I. coccinea extract at doses of 1000 and 1500 mg kg-1 suppressed eosinophilia and significantly inhibited AHR in rat with OVA-induced asthma. Based on lung histopathological study using hematoxylin and eosin I. coccinea reduced inflammatory cell infiltration and repaired epithelial cells damaged. In addition the extract at the same doses significantly decreased the diameter of the blue spot (16 and 55%, respectively) compared with the controls and inhibited the skin reactions induced by histamine (23.55 and 53.36%, respectively). In conclusion our results provide evidence that I. coccinea has anti-asthmatic properties and then can support its use in folk medicine to treat asthma.
Received: May 12, 2011;
Accepted: June 10, 2011;
Published: August 17, 2011
Herbal medicines are widely used for the treatment and prevention of various
diseases in Africa and other developing countries of the world (Diallo
et al., 2009, 2010). Ixora coccinea
Linn (Rubiaceae) has been reported to have anti-inflammatory activity in the
carrageenan-induced paw oedema test in rats and anti-mitotic activity (Ratnasooriya
et al., 2005a; Zachariah et al., 1994).
Its flower has shown anti-tumour activity (Latha and Panikkar,
1998), chemoprotective and hepatoprotective effects (Latha
and Panikkar, 1999, 2001) and also are used in treatment
of dysentery, leucorrhoea, dysmenorrhoea. Leaves are used to treat diarrhoea.
The flowers and bark are used on reddened eyes and eruptions (Ratnasooriya
et al., 2005b). The plant is traditionally used for various respiratory
ailments including catarrhal bronchitis (Ghani, 2003),
cough and asthma (Missebukpo et al., 2007). Recently,
Missebukpo et al. (2007) demonstrated antitussive
effect of the hydroalcoholic extract of I. coccinea leaves. To our knowledge,
no studies have been performed to evaluate its anti-asthmatic properties.
Allergic asthma is one of the most common disorders encountered in clinic and
the mortality associated with allergic asthma has increased worldwide over the
last two decades (Renauld, 2001). Asthma is a chronic
inflammatory disease of the respiratory tract that is characterized by increased
Airway Hyper-Reactivity (AHR), infiltration of leucocytes, especially eosinophils
into airways, bronchial epithelial injury and mucus production that lead to
episodes of wheezing, coughing and shortness of breath (Busse
and Rosenwasser, 2003; Xiangping et al., 2006).
In allergic bronchial asthma, the stimulation of allergen-specific IgE production
is believed to contribute to the development of AHR (Broide
et al., 1991; Fang et al., 2005) which
has been attributed to chronic airway inflammation (Henderson
et al., 1997). Mast cells are important in the pathogenesis of asthma
: IgE, bound to its receptor FcRI on mast cells and other cells, triggers the
release of pre-formed and newly-mediators (Kay, 2005)
including histamine, leukotrienes and platelet activation factor which can potentially
induce AHR (Kawada et al., 2001).
Histamine is a primary amine released by mast cells and basophils after IgE
cross-linking by allergen with effects such as vasodilation mucus hypersecretion,
oedema and smooth muscle cell contraction (Marone et
al., 2003). It thought to be the most potent vasoactive mediator involved
in the acute phase of immediate allergic reaction (Dai et
al., 2004). Thus it also has pro-inflammatory properties through its
effect on macrophages, epithelial and endothelial cells. Cumulative evidence
suggests that histamine release may also have a pathophysiologic role in allergic
asthma (Gelfand, 2002). As most allergic and inflammatory
effects of histamine are mediated by binding to H1 receptors, for
this purpose, H1 receptor antagonists are widely used to treat allergies (White,
Therefore, in the present study we investigated the therapeutic potential of the hydroalcoholic extract of I. coccinea leaves on allergic airway inflammation and AHR in a murine model of allergic asthma and its effect in histamine receptor.
MATERIALS AND METHODS
Plant material: The leaves of I. coccinea were collected from
Lomé not far from University of Lomé (Togo) in July 2007. The
plant was authenticated by Professor Akpagana Koffi from Laboratory of Botanic
and Plant Ecology (Faculty of Science/University of Lomé). A voucher
specimen was deposited at the herbarium under the number TOGO 12671 of this
Laboratory. The leaves were washed under running water, air-dried and cut into
small pieces. The dried sample was extracted in water/ethanol mixture (1:1)
for 72 h with manual discontinue agitation. The solution was filtered and evaporated
using a rotary evaporator (Buchi R120) set at 45°C to obtain a dry extract
which contained alkaloids, flavonoids and tannins as revealed by phytochemical
screening previously (Missebukpo et al., 2007).
Animals: Wistar rats (150-200 g) of either sex were housed in standard conditions temperature relative humidity and 12 h light/dark cycle. They were fed with standard diet and water ad libitum and were kept in the Animal House of the Faculty of Sciences of University of Lomé (Togo).
Sensitization and challenge procedure: The rats were actively sensitized
by intraperitoneal injections of 20 mg ovalbumin with 100 mg Al(OH)3
(chicken OVA, grade V, Sigma Chemical Co., St Louis, MO) as described by Agbonon
et al. (2005). Rats were challenged intranasally (i.n) (Henderson
et al., 1997) on days 24, 25, 26 and 27. Control animals received
i.p saline with Al (OH)3 on days 0, 3, 7 and 21 and (i.n) saline
without Al(OH)3 on days 24, 25, 26 and 27. Twenty-four hours after
the last OVA challenge, the rats were prepared for the collection of Bronchoalveolar
Lavage Fluid (BALF) or for the assessment of AHR to methacholine or for histological
Treatment protocol: The extract (1 and 1.5 g kg-1) was dissolved in distilled water and administered orally for 4 consecutive days 1 h before every intranasal challenge (from day 24 to day 27) and 1 h before BALF collection or MCh administration.
BALF study: To evaluate airway inflammation we examined the accumulation
of inflammatory cells in BALF. Experiments were performed according to previously
described methods (Agbonon et al., 2005). The
remaining samples of BALF were centrifuged at 2500 trs min-1 for
10 min (Electric Centrifuge SPN-400 Japan). Cells were fixed and stained using
May-Grünwald-Giemsa (RHONE-POULENC, France). Eosinophil count was performed,
using standard morphologic criteria, by a naïve observer. The eosinophil
% was expressed as a percentage of the total leukocytes.
Histological study: After BAL collection, bronchial and lung were removed
from the chest cavity and fixed in 10% formaldehyde. Lobes were isolated, embedded
in paraffin and sectioned at 5 μm. Tissue sections were stained with haematoxylin
eosin (H and E) for general morphology (McManus and Mowry,
1965; McKay et al., 2004; Rogerio
et al., 2007).
Assessment of AHR to methacholine: Measurement of bronchial responsiveness
to methacholine (Sigma, Germany) was carried out according to Hannon
et al. (2001). Pulmonary Inflation Pressure (PIP) was measured with
pressure transducer (BIOPAC SYSTEM, MODEL MP100, HAVARD APPARATUS) with a computer
(logiciel Acq Knowledge III). The response was measured as the peak increase
above the baseline immediately after MCh administration.
Inhibitory effect on anaphylactic reaction (abdominal wall method):
The experiments were carried out according to a method reported previously (Kataoka
et al., 1997, 2002). Extract (1 and 1.5 g
kg-1) and Citirizine (Pharmacy) at 10 mg kg-1 were administered
orally to rats and control rats were administered distilled water alone. The
anti-allergic activity (type I) was expressed as the percentage inhibition compared
with the control group.
where, D is diameter of the bleu area.
Histamine-induced cutaneous reactions: Rats were given orally test drugs
and were anesthetized by i.p. injection of 1 g kg-1 urethane according
to the previously described method (Dai et al., 2004;
Saito et al., 2004).
The anti-histaminic activity was expressed by calculating the area (A) of the dye spot as follows:
where, R is the long radius and r is the short radius.
The inhibitory effects of the test drugs were expressed as the percent reduction of dye leakage compared with the control group.
Statistical analysis: Experimental data are presented as Means±S.E.M. Data were analyzed by one-way analysis of variance (ANOVA) followed by Fishers test with multiple comparisons. The p-values <0.05 were regarded as significant. All statistical analysis were carried out using the Instat Statistical package (Graph Pad software, Inc. USA).
Effect of I. coccinea extract on airway inflammation: To investigate
the anti-asthmatic effect of I. coccinea extract in vivo, asthma was
induced in rat using OVA. The total number of leukocytes and the alteration
of the cellular component in BALF of rat were evaluated. OVA challenge in OVA-sensitized
rat caused a marked infiltration of leukocytes recovered in BALF by 4.92-fold
as compared with that in the control-saline group (Fig. 1).
||Effect of I. coccinea extract on antigen-induced increases
in leukocytes in BAL obtained from rats. The extract was given orally 4
consecutive days before antigen challenge and 1 h before animal was killed.
BAL was obtained 24 h after the last challenge. Each value represents the
Mean±S.E.M. (N = 6). **p<0.001 treated vs control OVA; ##p<0.001
control saline vs control OVA
||Effect of I. coccinea extract on antigen-induced increases
in eosinophils in BALF obtained from rats. The extract was given orally
4 consecutive days before antigen challenge and 1 h before animal was killed.
BALF was obtained at 24 h after the last challenge. Eosinophils from BALF
were counted using a hematocytometer and stained with May-Grünwald-Giemsa.
The eosinophil % was expressed as a percentage in total leukocytes. Each
value represents the Mean±S.E.M. (N = 6). **p<0.001 treated vs
control OVA; ##p<0.001 control saline vs control OVA
In the control OVA, there are in BALF 25.65-fold eosinophils, as compared that
in the control-saline group. Treatment with I. coccinea extract by oral
administration at doses of 1 and 1.5 g kg-1 decreased the number
of BALF leukocytes by 61.8 and 70.27% compared with the control-OVA group (p<0.001)
(Fig. 1) and also reduced the number of eosinophils by 97.53
and 98.60%, respectively (p<0.001) (Fig. 2).
Histological study: Histological examination revealed that the lungs of control-saline rat were normal in appearance without inflammatory cells in the airways (Fig. 3a) whereas the control-OVA group showed a marked infiltration of inflammatory cells, in peribronchial and perivascular spaces and alveolar walls (Fig. 3b). I. coccinea treatment (1.5 g kg-1) markedly reduced the inflammatory changes in OVA-sensitized/challenged rat and repaired epithelium damage (Fig. 3c).
I. coccinea inhibits antigen-induced AHR: We found that immunised
rats challenged with OVA (control OVA) developed AHR to increasing doses of
methacholine when compared with control saline (Fig. 4a, b).
I. coccinea at 1.5 g kg-1 suppressed airway hyperresponsiveness
significantly when compared with control OVA (p<0.05) (Fig.
Inhibitory effect on anaphylactic reaction (abdominal wall method):
As shown in Fig. 5, oral administration of I. coccinea
extract significantly decreased the diameter of the blue spot compared
with the controls.
|Fig. 3 (a-c):
||Histological evidence of decreased lung inflammation in rat
treated with extract of I. coccinea (1.5 g kg-1 orally).
Paraffin-embedded. Hematoxylin and eosin-stained lung sections from each
group of five rats is shown. (a) Non sensitised rat given saline challenge.
(b) OVA-challenged rat; peribronchial and perivascular inflammatory cells
(IC), epithelium (E) damaged, surrounding blood vessel (BV) structures and
mucosal hyperplasia are seen. (c) OVA-challenged rat plus treatment with
extract of I. coccinea; a reduction in inflammatory cells is seen,
no mucosal hyperplasia and epithelium repaired
Also, the anti-allergic effect of 1500 mg kg-1 body weight of I.
coccinea was lightly superior than that of the 10 mg kg-1 body
weight of citirizine (55 and 40.28%, respectively) which has been widely used
against allergic disorder as histamine H1-receptor antagonist.
Histamine-induced cutaneous reactions: Cutaneous reactions were elicited
by an intradermal injection of histamine; I. coccinea (1 and 1.5 g kg-1
p.o.) reduced the skin reaction induced by histamine at 23.55 and 53.36%, respectively
|Fig. 4 (A-B):
||Effect of I. coccinea extract (1.5 g kg-1)
on antigen-induced BHR in rats. The extract was given orally 4 consecutive
days before antigen challenge and 1 h before MCh administration. AHR was
measured 24 h after the final OVA challenge and increasing concentrations
of MCh (5-50 μg mL-1 i.v.) were administered with a 2 min
interval between doses; (A) Representative traces showing the effects of
extract (1.5 g kg-1) on MCh-induced increases in PIP, (a) saline
control, (b) control OVA and (c) rat sensitized, challenged and treated
with I. coccinea extract (1.5 g kg-1); (B) Graph showing
inhibiting effect of I. coccinea extract (1.5 g kg-1)
on MCh-induced increases in PIP. Airway hyperresponsiveness was assessed
by percentage change from the baseline level of PIP. Each value represents
the Mean±S.E.M. (N = 6-9) per treatment group. *p<0.05 vs control
OVA. They are analyzed by one-way ANOVA followed by Fishers test
A rat model of allergic asthma was used to evaluate the anti-asthmatic effects
of I. coccinea in vivo. Airway hyperreactivity to direct or indirect
stimuli is a cardinal feature of asthma (Wyss et al.,
||Type I anti-allergic activities of the hydroalcoholic extract
of I. coccinea leaves. Rats were sensitized intraperitoneally with
OVA in alum (1 : 5) on day 0. On day 14 distilled water, extract (1000 and
1500 mg kg-1) and citirizine as reference compound (10 mg kg-1)
were administered orally 1 h before to challenge on the abdominal wall with
OVA (4 mg mL-1). Control saline was not sensitized and not challenged.
The results are expressed as Means±S.E.M. (N = 5-9) *p<0.05, **p<0.001
as compared with control OVA group, #p<0.05, ##p<0.001
compared to the control saline group and analyzed by one-way ANOVA followed
by Fishers test
||Effect of the hydroalcoholic extract of I. coccinea
leaves on the histamine-induced cutaneous reaction. Histamine (0.5 mg kg-1)
was intradermally injected into spots on the dorsal skin of rats. There
after, 1% of Evans blue was immediately injected in the tail vein. Extract
and citirizine (reference compound) were orally administered 1 h before
challenge. Control saline group was injected saline intradermally. Rats
were sacrificed 30 min after the induction of reactions and the amount of
dye that leaked into the spots was determined. The results are expressed
as Means±S.E.M. (N = 5) **p<0.01, ***p<0.001 as compared with
control Histamine group; #p<0.05, ##p<0.001
compared to the control saline group and analyzed by one-way ANOVA followed
by Fishers test
In the present study the extract clearly inhibited antigen-induced AHR. There
is convincing evidence that AHR occurs as a consequence of epithelial damage
resulting from the accumulation of large numbers of activated eosinophils and
mast cells within the respiratory tract (Bradley et al.,
1991). Eosinophils that migrated to the site of inflammation have been shown
to play a causative role in tissue damage by releasing cytotoxic granules, proteins
and tissue-damaging superoxide (Wu et al., 2000;
Palmqvist et al., 2007) they are the central
effector cells that are responsible for ongoing airway inflammation (Kay,
2005; Shen, 2005), the main source of lipid mediators
that play major roles in the pathogenesis of asthma and other forms of allergic
inflammation (Bandeira-Melo and Weller, 2003). Thus
we investigated the effect of I. coccinea extract on pulmonary eosinophilia.
The result indicated a significant (p<0.05) inhibition of OVA-induced eosinophilia
in rat. In addition to the decreased percentages of granulocytes in BALF we
also observed less cellular infiltration around airways and blood vessels in
lungs of rats treated with I. coccinea extract. Histological studies
confirmed also airway protective effect of extract. This is in accordance with
Shen et al. (2003) and Justice
et al. (2003) who demonstrated that AHR is eosinophil dependant.
Since, histamine may be a dominant pathophysiologic factor of asthma (Kitamura,
2005) and inflammation and symptoms that ensue may be susceptible to H1-receptor
antagonist blockade (Gelfand, 2002) we investigated
on the one hand, the effect of the extract on immediate allergic response with
AW method and on the other hand, its anti-histaminic effect with histamine-induced
cutaneous reaction. The AW method is one of simplest techniques for inducing
and detecting anaphylactic reaction in vivo models (Kataoka
et al., 1997, 2002). In sensitised rats,
chemical mediators such as histamine and leukotrienes are released from mast
cells upon allergen challenge, followed by an increase in the vascular permeability
of the abdominal wall (Kataoka et al., 1997).
In present study oral administration of I. coccinea extract decreased
significantly the diameter of the blue spot compared with the control groups.
The anti-allergic effect of 1.5 g kg-1 of I. coccinea extract
was slightly higher than that of the 10 mg kg-1 of citirizine which
has widely used against allergic disorders as a histamine H1-receptor
antagonist. However this effect is lower than that obtained with citirizine
in histamine-induced vasodilatation in rat skin. Thus the inhibition of the
diameter of the spot may be due to an effect of the I. coccinea extract:
(1) as a histamine H1 receptor blocker, since I. coccinea
extract shows antihistaminic action in intradermal histamine-induced vasodilatation
in rat skin. These results corroborates those obtain by Ratnasooriya
et al. (2005a) who showed anti-histaminic activity of the aqueous
leaf extract of I. coccinea. (2) as an inhibitor of mast cells degranulation
since the increase in vascular permeability was dependent on the histamine concentration
(Kataoka et al., 1997).
Mast cells activation contributed to the induction of enhanced airway responsiveness
and chronic inflammatory including eosinophil and lymphocyte infiltration (Nauta
et al., 2008; Yu et al., 2006). According
to Kawada et al. (2001), drugs which inhibited
PCA in rat suppressed the mast cell activation. Therefore, the dose of 1500
mg kg-1 of our extract was sufficient to suppress the mast cell activation,
because it clearly inhibited antigen-specific anaphylaxis in rat using abdominal
wall as a challenge site.
These results are the first to provide experimental evidence demonstrating that I. coccinea has anti-asthmatic activities in in vivo on animal model. In the rat model of asthma used, I. coccinea extract effectively suppressed two important pathological characteristics of asthma such as airway inflammation and airway hyperreactivity. In addition the extract has shown inhibitory effect on immediate allergic reactions which is probably mediated by reducing the release of mediators such as histamine from mast cells or acted as H1-receptor antagonist.
Even though the results obtained here are not sufficient to prove the mechanism of I. coccinea in the inhibition of allergic and inflammatory reactions. Further investigations are needed to clarify the active components and precise mechanism of I. coccinea. However, this study could confirm the traditional use of I. coccinea on the treatment of asthma.
Agbonon, A., K. Aklikokou, K. Eklu-Gadegbeku, K. Akpagana and M. Gbeassor, 2005.
Effect of ethanolic extract of Pluchea ovalis
root in asthma model of Wistar rat. BLACPMA, 4: 52-59.
Bandeira-Melo, C. and P.F. Weller, 2003.
Eosinoplis and cysteniyl leukotries. Prostaglandins Leukotr. Essential Fatty Acids, 69: 135-143.CrossRef | PubMed | Direct Link |
Bradley, B.I., M. Azzawi, M. Jacobson, B. Assoufi and J.V. Collins et al
Eosinophils, T-lymphocytes, mast cells, neutrophils and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal subjects and relationship to bronchial hyperresponsiveness. J. Allergy Clin. Immunol., 88: 661-674.PubMed | Direct Link |
Broide, D.H., G.J. Gleich, A.J. Cuomo, D.A. Cobum, E.C. Federman, L.B. Schwartz and S.I. Wasseman, 1991.
Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J. Allergy Clin. Immunol., 88: 637-648.CrossRef | PubMed | Direct Link |
Busse, W.W. and L.J. Rosenwasser, 2003.
Mechanisms of asthma. J. Allergy Clin. Immunol., 111: S799-S804.CrossRef | PubMed |
Dai, Y., L.F Hou, Y.P. Chan, L. Cheng and P.P.H. But, 2004.
Inhibition of allergic reactions by ethanol extract from Plumbago zeylanica stem. Biol. Pharm. Bull., 27: 429-432.PubMed | Direct Link |
Diallo, A., K. Eklu-Gadegkeku, T. Mobio, S. Moukha and A. Agbonon et al
Protective effect of Moringa oleifera
Lam. and Lannea kerstingii
extracts against cadmium and ethanol-induced lipid peroxidation. J. Pharma. Toxicol., 4: 160-166.CrossRef | Direct Link |
Diallo, A., K. Eklu-Gadegbeku, A. Agbonon, K. Aklikokou, E.E. Creppy and M. Gbeassor, 2010.
Acute and sub-chronic (28-Day) oral toxicity studies of hydroalcoholic extract of Lannea kerstingii
Engl. and K. Krause (Anacardiaceae) stem bark. J. Pharmacol. Toxicol., 5: 243-349.CrossRef | Direct Link |
Fang, S.P., T. Tanaka, F. Tago, T. Okamoto and S. Kojima, 2005.
Immunomodulatory effects of Gyokuheifusan on IFN-γ/IL-4 (Th1/TH2) balance in ovalbumin (OVA)-induced asthma model mice. Biol. Pharm. Bull., 28: 829-833.PubMed | Direct Link |
Gelfand, E.W., 2002.
Role of histamine in pathophysiology of asthma: Immunomodulatory and anti-inflammatory activities of H1
-receptor antagonists. Am. J. Med., 113: 2S-7S.PubMed | Direct Link |
Ghani, A., 2003.
Medicinal Plants of Bangladesh with Chemical Constituents and Uses. 2nd Edn., Asiatic Society of Bangladesh, Dhaka, Bangladesh, Pages: 603
Hannon, J.P., B. Tigani, I. Williams, L. Mazzoni and J.R. Fozard, 2001.
Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway rats. Br. J. Pharmacol., 132: 1509-1523.PubMed | Direct Link |
Henderson, W.R., E.Y. Chi, R.K. Albert, S.J. Chu and W.J. Lamm et al
Blockade of CD49d (α4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in mouse model of asthma. J. Clin. Invest., 100: 3083-3092.CrossRef | PubMed | Direct Link |
Justice, J.P., M.T. Borcher, J.R. Crosby, E.M. Hines and H.H. Shen et al
Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology. Am. J. Physiol. Lung Cell. Mol. Physiol., 284: L169-L178.PubMed | Direct Link |
Kataoka, H, S. Horiyama, M. Yamaki, H. Oku and K. Ishiguro et al
Anti-inflammatory and anti-allergic activities of hydroxylamine and related compounds. Biol. Pharm. Bull., 25: 1436-1441.CrossRef | PubMed | Direct Link |
Kataoka, H., Y. Tsuda, A. Baba, H. Yoshida and R. Hirasawa et al
A novel method for induction and detection of anaphylactic reaction using the mouse Abdominal Wall (AW) method. Biol. Pharm. Bull., 20: 714-716.PubMed | Direct Link |
Kawada, N., H. Tanaka, T. Takizawa, T. Yamada and Y. Takahashi et al
Role of mast cells in antigen-induced airway inflammation and bronchial hyperresponsiveness in rats. Jpn. J. Pharmacol., 85: 250-259.PubMed | Direct Link |
Kay, A.B., 2005.
The role of eosinophils in the pathogenesis of asthma. Trends Mol. Med., 11: 148-152.CrossRef | PubMed | Direct Link |
Kitamura, Y., 2005.
Recent progress of mast cell research. Arerugi, 54: 45-47.PubMed | Direct Link |
Latha, P.G. and K.R. Panikkar, 1998.
Cytotoxic and antitumor principles from Ixora coccinea
flowers. Cancer Lett., 130: 197-202.PubMed | Direct Link |
Latha, P.G. and K.R Panikkar, 2001.
Chemoprotective effect of Ixora coccinea
L. flowers on cisplatin induced toxicity in mice. Phytother. Res., 15: 364-366.CrossRef | PubMed | Direct Link |
Marone, M., A. Genovese and M. Triggiani, 2003.
The histamine-cytokine network in allergic inflammation. J. Allergy Clin. Immunol., 112: S83-S88.PubMed | Direct Link |
McKay, A., B.P. Leung, I.B. McInnes, N.C. Thomson and F.Y. Liew, 2004.
A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J. Immunol., 172: 2903-2908.PubMed | Direct Link |
McManus, J.F.A. and R.W. Mowry, 1965.
Stainning Methods, Histologic and Histochemical. Harper Raw, New York, Evanston, London.
Missebukpo, A., A. Agbonon, K. Eklu-Gadegbeku, K. Aklikokou and M. Gbeassor, 2007.
Etude de l'activite biologique Ixora coccinea
L. (Rubiaceae) et de Maytenus senegalensis
(Lam) Excell (Celastraceae); plantes a propriete antitussive. (Antitussive study of Ixora coccinea
L. (Rubiaceae) and Maytenus senegalensis
(Lam) Excell (Celastraceae). Annale de l'Universite de Lome, University of Lome Annale, Tome 14, pp: 73-84.
Nauta, A.J., F. Engels, L.M. Knippels, J. Garssen, F.P. Nijkamp and F.A. Redegeld, 2008.
Mechanisms of allergy and asthma. Eur. J. Pharmacol., 585: 354-360.PubMed | Direct Link |
Palmqvist, C., A.J. Wardlaw and P. Bradding, 2007.
Chemokine and their receptors as potential target for the treatment of asthma. Br. J. Pharmacol., 15: 725-736.CrossRef | Direct Link |
Ratnasooriya, W.D., S.A. Deraniyagala, S.D.N.K. Bathige, C.L. Goonasekara and J.R.A.C. Jayakody, 2005.
Antinociceptive action of aqueous extract of the leaves of Ixora coccinea
. Acta Biologica Hungarica, 56: 21-34.CrossRef | Direct Link |
Ratnasooriya, W.D., S.A. Deraniyagala, G. Galhena, S.S.P. Liyanage, S.D.N.K. Bathige and J.R.A.C. Jayakody, 2005.
Anti-inflammatory activity of aqueous leaf extract of Ixora coccinea
. Pharm. Biol., 43: 147-152.Direct Link |
Zachariah, R., C.R.S. Nair and P.V. Panicker, 1994.
Anti-inflammatory and anti-mitotic activities of lupeol isolated from the leaves of Ixora coccinea
Linn. Ind. J. Pharm. Sci., 56: 129-132.Direct Link |
Renauld, J.C., 2001.
New insights into the role of cytokines in asthma. J. Clin. Pathol., 54: 577-589.PubMed | Direct Link |
Rogerio, A.P., C. Fontanari, E. Borducchi, A.C. Keller and M. Russo et al
Anti-inflammatory effects of Lafoensia pacari
and ellagic acid in a murine model of asthma. Eur. J. Pharmacol., 580: 262-270.CrossRef | PubMed | Direct Link |
Saito, S.Y., Y. Maruyama, S. Kamiyama, N. Nakahata and Y. Ohizumi, 2004.
Ephedrae herba in Mao-Bushi-Saishin-To inhibits IgE-mediated histamine release and increases cAMP content in RBL-2H3 cells. J. Pharmacol. Sci., 95: 41-46.PubMed | Direct Link |
Shen, H.H., S.I. Ochukur, M.P. McGarry, J.R. Crosby and E.M. Hines et al
A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse. J. Immunol., 170: 3296-3305.PubMed | Direct Link |
Shen, H.H., 2005.
Eosinophil: Central mediator of allergic asthma? Chin. Med. J., 118: 4-5.PubMed | Direct Link |
White, M.V., 1990.
The role of histamine in allergic diseases. J. Allergy Clin. Immunol., 86: 599-605.PubMed | Direct Link |
Wu, W., M.K. Samoszuk, S.A. Comhair, M.J. Thomassen and C.F. Farver et al
Eosinophils generate brominating oxidants in allergen-induced asthma. J. Clin. Invest., 105: 1455-1463.CrossRef | PubMed | Direct Link |
Wyss, D., O. Bonneau and A. Trifilieff, 2005.
Mast cell involvement in the adenosine mediated airway hyper-reactivity in murine model of ovalbumin-induced lung inflammation. Br. J. Pharmacol., 145: 845-852.CrossRef | PubMed | Direct Link |
Xiangping, C., X. Zhaohui, W. Dazheng, Z. Aihua, Z. Mingmei, Q. Mingfeng and J. Wei, 2006. In vitro
and in vivo
evaluation of the anti-asthmatic activities of fractions from Pheretima
. J. Ethnopharmacol., 111: 490-495.PubMed | Direct Link |
Yu, M., M., Tsai, S.Y. Tam, C. Jones, J. Zehnder and S.J. Galli, 2006.
Mast cells can promote the development of multiple features of chronic asthma in mice. J. Clin. Invest., 116: 1633-1641.PubMed | Direct Link |